期刊文献+

维生素D受体基因FokⅠ多态性与前列腺增生临床进展的关系 被引量:6

下载PDF
导出
摘要 目的分析维生素D受体(VDR)基因FokⅠ位点单核苷酸多态性与良性前列腺增生(BPH)发生临床进展的关系。方法应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)对200例行手术治疗的BPH患者(进展组)和200例未行手术治疗的BPH患者(对照组)进行FokⅠ多态性检测,分析两组患者间的临床资料(前列腺体积、I-PSS评分、PSA、尿流率等)以及两组间基因型和等位基因的频率分布情况。结果两组患者的年龄差异无统计学意义(P>0.05),前列腺体积、PSA、I-PSS评分以及尿流率差异有统计学意义(P<0.05)。FokⅠ多态位点3种基因型的基因频率分布均符合Hardy-Weinberg定律。FokⅠ多态位点FF、Ff、ff基因型在进展组与对照组的分布频率分别为:25.5%(51/200),39.5%(79/200);35%(70/200)和33%(66/200);43%(86/200),24%(48/200),差异有统计学意义(P<0.05)。两组中等位基因F、f的分布频率分别为:45.25%(181/400),54.75%(219/400)和54.5%(218/400),45.5%(182/400),差异有统计学意义(P<0.05)。结论 VDR基因FokⅠ多态性与BPH发生临床进展有相关性。
出处 《广东医学》 CAS CSCD 北大核心 2014年第8期1219-1221,共3页 Guangdong Medical Journal
基金 国家自然科学基金面上项目(编号:81272849) 广州市医药卫生科技项目(编号:20131A011045)
  • 相关文献

参考文献11

  • 1ESPINOSA G,ESPOSITO R,KAZZAZI A,et al.Vitamin D and benign prostatic hyperplasia-areview[ J].Can J Urol,2013,20(4):6820-6825.
  • 2SANCHEZ NINO M D,BOZIC M,CORDOBA LANIJS E,et al.Beyond proteinuria:VDR activation reduces renal inflammation in experimental diabetic nephropathy [J].Am J Physiol Renal Physiol,2012,302(6):647-657.
  • 3阮黎,钟惟德,李正明,华兴.维生素D受体基因FokⅠ多态性与良性前列腺增生合并组织学前列腺炎的关系[J].中华男科学杂志,2011,17(10):880-883. 被引量:11
  • 4FWU C W,EGGERS P W,KAPLAN S A,et al.Long-term effects of doxazosin,finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia[ J].J Urol,2013,190(1):187-193.
  • 5PEJCIC T P,TULIC CDZ,LALIC N V,et al.Urinary prostate-specific antigen:predictor of benign prostatic hyperplasia progres-sion? [J].Can J Urol,2013,20(2):6707-6713.
  • 6KWON H,KANG H C,LEE J H.Relationship between predic-tors of the risk of clinical progression of benign prostatic hyperplasi-a and metabolic syndrome in men with moderate to severe lower u-rinary tract symptoms[J].Urology,2013,81(6):1325-1329.
  • 7GANDAGL1A G,BRIGANTI A,GONTERO P,et al.The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia(BPH)[ J].BJU Int,2013,112(4):432-441.
  • 8HUANG T,QI J,YU Y,et al.Transitional zone index and intra-vesical prostatic protrusion in benign prostatic hyperplasia patients:correlations according to treatment received and other clinical data [J].Korean J Urol,2012,53(4):253-257.
  • 9BROOKES A J.The essence of SNPs[J].Gene,1999,234(2):177-186.
  • 10GU X,NA R,HUANG T,et al.SRD5A1 and SRD5A2 are asso-ciated with treatment for benign prostatic hyperplasia with the com-bination of 5α-reductase inhibitors and α-adrenergic receptor antagonists[J].JUrol,2013,190(2):615-619.

二级参考文献7

共引文献10

同被引文献49

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部